# Elio Scarpini

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/elio-scarpini/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,551 |
| Field | Alzheimer's disease research and treatments |
| h-index | 88 |
| i10-index | 398 |
| OpenAlex ID | https://openalex.org/A5023350680 |
| ORCID iD | https://orcid.org/0000-0002-6395-2119 |
| Works | 720 |

## Researcher papers

- [Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease](https://scholariq.org/papers/trial-of-solanezumab-for-mild-dementia-due-to-alzheimer-s-disease/)
- [APOE and Alzheimer disease: a major gene with semi-dominant inheritance](https://scholariq.org/papers/apoe-and-alzheimer-disease-a-major-gene-with-semi-dominant-inheritance/)
- [Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference](https://scholariq.org/papers/uncovering-the-heterogeneity-and-temporal-complexity-of-neurodegenerative/)
- [The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers](https://scholariq.org/papers/the-alzheimer-s-association-external-quality-control-program-for-cerebrospinal/)
- [Frontotemporal dementia and its subtypes: a genome-wide association study](https://scholariq.org/papers/frontotemporal-dementia-and-its-subtypes-a-genome-wide-association-study/)
- [Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension](https://scholariq.org/papers/effect-of-natalizumab-on-disease-progression-in-secondary-progressive-multiple/)
- [Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores](https://scholariq.org/papers/common-variants-in-alzheimer-s-disease-and-risk-stratification-by-polygenic-risk/)
- [Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study](https://scholariq.org/papers/age-at-symptom-onset-and-death-and-disease-duration-in-genetic-frontotemporal/)
- [Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders](https://scholariq.org/papers/recommendations-to-distinguish-behavioural-variant-frontotemporal-dementia-from/)
- [Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study](https://scholariq.org/papers/conversion-from-clinically-isolated-syndrome-to-multiple-sclerosis-a-large/)
- [<i>SQSTM1</i> mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis](https://scholariq.org/papers/i-sqstm1-i-mutations-in-frontotemporal-lobar-degeneration-and-amyotrophic/)

## Researcher topics

- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)
- [Amyotrophic Lateral Sclerosis Research](https://scholariq.org/topics/amyotrophic-lateral-sclerosis-research/)
- [Dementia and Cognitive Impairment Research](https://scholariq.org/topics/dementia-and-cognitive-impairment-research/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Neuroinflammation and Neurodegeneration Mechanisms](https://scholariq.org/topics/neuroinflammation-and-neurodegeneration-mechanisms/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.